Here, NSCLC biopsies and adjacent non-cancerous tissues were examined for expression of TGFβR2. The overall survival in patients with high expression (> 1.99 fold) of TGFβR2 was decreased relative to patients with low expression of TGFβR2. In addition, clinical parameters such as lymph node metastasis and tumor size were associated with a worse prognosis in this cohort. The gene discussed is TGFBR2; the disease is metastatic malignant neoplasm in the lymph nodes.